396 results on '"NEUROPATHY"'
Search Results
2. Application of the 2021 EAN/PNS criteria for chronic inflammatory demyelinating polyneuropathy.
- Author
-
Rajabally, Yusuf A., Afzal, Saadia, Lay Khoon Loo, Goedee, H. S., and Loo, Lay Khoon
- Subjects
PERIPHERAL nervous system ,GUILLAIN-Barre syndrome ,RETROSPECTIVE studies ,NEUROLOGY ,SENSITIVITY & specificity (Statistics) ,NEURAL conduction ,IMPACT of Event Scale - Abstract
Background: The diagnostic value of new criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) for chronic inflammatory demyelinating polyneuropathy (CIDP) is unknown.Methods: We performed a retrospective study of fulfilment of EAN/PNS 2021 criteria on 120 consecutive patients with a clinical diagnosis of 'suspected CIDP' and objective treatment response, attending University Hospitals Birmingham, UK. Specificity was evaluated versus 100 consecutive controls.Results: The sensitivity of EAN/PNS criteria for 'CIDP' was 83.3%. The sensitivity for 'CIDP' or 'possible CIDP' was 93.3%. Specificity was of 94% for 'CIDP' and 79% for 'CIDP' or 'possible CIDP'. No sensitivity/specificity differences were ascertained with previous versions ('CIDP': sensitivity: 83.3% vs 81.3%, p=0.74, specificity: 94% vs 96.1%, p=0.38, respectively; 'CIDP' or 'possible CIDP': sensitivity: 93.3% vs 96.7%, p=0.25 and specificity: 79% vs 69.2 %, p=0.09, respectively). F-wave prolongation, proximal and distal temporal dispersion were the most likely parameters to contribute to false positives, whereas distal motor latency was the least likely. No impact of sensory electrophysiology could be ascertained. 'Typical CIDP' represented 79% of the CIDP cohort. The largest component of the 'variant CIDP' group was represented by focal/multifocal forms (14%). With new criteria, 6.7% of the cohort did not meet requirements, among whom the majority (75%) had paranodopathy or chronic immune sensory polyradiculopathy (CISP).Discussion: The sensitivity and specificity of new EAN/PNS criteria for CIDP is equivalent to that of previous versions. The exclusion of paranodopathies and CISP from the CIDP spectrum impacts on management of a non-negligible proportion of treatment-responsive patients. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
3. Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy.
- Author
-
Doneddu, Pietro Emiliano, De Lorenzo, Alberto, Manganelli, Fiore, Cocito, Dario, Fazio, Raffaella, Briani, Chiara, Mazzeo, Anna, Filosto, Massimiliano, Cosentino, Giuseppe, Benedetti, Luana, Schenone, Angelo, Marfia, Girolama Alessandra, Antonini, Giovanni, Matà, Sabrina, Luigetti, Marco, Liberatore, Giuseppe, Spina, Emanuele, Peci, Erdita, Strano, Camilla, and Cacciavillani, Mario
- Subjects
PERIPHERAL nervous system ,GUILLAIN-Barre syndrome ,RETROSPECTIVE studies ,NEUROLOGY ,NEURAL conduction ,SENSITIVITY & specificity (Statistics) - Abstract
Objectives: To compare the sensitivity and specificity of the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) with those of the 2010 European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS).Methods: Sensitivity and specificity of the two sets of criteria were evaluated in 330 patients with CIDP and 166 axonal peripheral neuropathy controls. Comparison of the utility of nerve conduction studies with different number of nerves examined and of the sensitivity and specificity of the two criteria in typical CIDP and its variants were assessed.Results: EFNS/PNS criteria had a sensitivity of 92% for possible CIDP and 85% for probable/definite CIDP, while the EAN/PNS criteria had a sensitivity of 83% for possible CIDP and 74% for CIDP. Using supportive criteria, the sensitivity of the EAN/PNS criteria for possible CIDP increased to 85% and that of CIDP to 77%, remaining lower than that of the EFNS/PNS criteria. Specificity of the EFNS/PNS criteria was 68% for possible CIDP and 84% for probable/definite CIDP, while the EAN/PNS criteria had a specificity of 88% for possible CIDP and 98% for CIDP. More extended studies increased the sensitivity of both sets of criteria by 4%-7% but reduced their specificity by 2%-3%. The EFNS/PNS criteria were more sensitive for the diagnosis of typical CIDP while the EAN/PNS criteria were more specific for the diagnosis of distal and sensory CIDP.Conclusions: In our population, the EAN/PNS criteria were more specific but less sensitive than the EFNS/PNS criteria. With the EAN/PNS criteria, more extended nerve conduction studies are recommended to obtain an acceptable sensitivity while maintaining a high specificity. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
4. Skin biopsy and small fibre neuropathies: facts and thoughts 30 years later.
- Author
-
Lauria, Giuseppe, Faber, Catharina G., and Cornblath, David R.
- Published
- 2022
- Full Text
- View/download PDF
5. IVIg-exposure and thromboembolic event risk: findings from the UK Biobank.
- Author
-
Kapoor, Mahima, Hunt, Ian, Spillane, Jennifer, Bonnett, Laura Jayne, Hutton, Elspeth Jane, McFadyen, James, Westwood, John-Paul, Lunn, Michael P., Carr, Aisling S., and Reilly, Mary M.
- Abstract
Background: Arterial and venous thromboembolic events (TEEs) have been associated with intravenous Ig use, but the risk has been poorly quantified. We aimed to calculate the risk of TEEs associated with exposure to intravenous Ig.Methods: We included participants from UK Biobank recruited over 3 years, data extracted September 2020.The study endpoints were incidence of myocardial infarction, other acute ischaemic heart disease, stroke, pulmonary embolism and other venous embolism and thrombosis.Predictors included known TEE risk factors: age, sex, hypertension, smoking status, type 2 diabetes mellitus, hypercholesterolaemia, cancer and past history of TEE. Intravenous Ig and six other predictors were added in the sensitivity analysis.Information from participants was collected prospectively, while data from linked resources, including death, cancer, hospital admissions and primary care records were collected retrospectively and prospectively. FINDINGS: 14 794 of 502 492 individuals had an incident TEE during the study period. The rate of incident events was threefold higher in those with prior history of TEE (8 .7%) than those without previous history of TEE (3.0%).In the prior TEE category, intravenous Ig exposure was independently associated with increased risk of incident TEE (OR=3.69 (95% CI 1.15 to 11.92), p=0.03) on multivariate analysis. The number needed to harm by exposure to intravenous Ig in those with a history of TEE was 5.8 (95% CI 2.3 to 88.3).Intravenous Ig exposure did not increase risk of TEE in those with no previous history of TEE.Interpretation: Intravenous Ig is associated with increased risk of further TEE in individuals with prior history of an event with one further TEE for every six people exposed. In practice, this will influence how clinicians consent for and manage overall TEE risk on intravenous Ig exposure. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
6. Exploratory analysis of lower limb muscle MRI in a case series of patients with SORD neuropathy.
- Author
-
O'Donnell, Luke Francis, Cortese, Andrea, Rossor, Alexander M., Laura, Matilde, Blake, Julian, Skorupinska, Mariola, Lunn, Michael P., Thornton, John S., Currò, Riccardo, Morrow, Jasper M., and Reilly, Mary M.
- Subjects
SMELL disorders ,MAGNETIC resonance imaging ,NEUROPATHY - Published
- 2023
- Full Text
- View/download PDF
7. Charcot-Marie-Tooth disease type 2CC due to variants causes a progressive, non-length-dependent, motor-predominant phenotype.
- Author
-
Pipis, Menelaos, Cortese, Andrea, Polke, James M., Poh, Roy, Vandrovcova, Jana, Laura, Matilde, Skorupinska, Mariola, Jacquier, Arnaud, Juntas-Morales, Raul, Latour, Philippe, Petiot, Philippe, Sole, Guilhem, Fromes, Yves, Shah, Sachit, Blake, Julian, Byung-Ok Choi, Ki Wha Chung, Stojkovic, Tanya, Rossor, Alexander M., and Reilly, Mary M.
- Subjects
RESEARCH ,NEURONS ,GENETIC mutation ,NERVE tissue proteins ,TIBIAL nerve ,RESEARCH methodology ,MAGNETIC resonance imaging ,MEDICAL cooperation ,EVALUATION research ,GENETIC carriers ,COMPARATIVE studies ,CHARCOT-Marie-Tooth disease ,GENOTYPES ,GENES ,RESEARCH funding ,GENETIC techniques ,CYTOPLASM ,GENEALOGY ,PHENOTYPES - Abstract
Objective: Neurofilaments are the major scaffolding proteins for the neuronal cytoskeleton, and variants in NEFH have recently been described to cause axonal Charcot-Marie-Tooth disease type 2CC (CMT2CC).Methods: In this large observational study, we present phenotype-genotype correlations on 30 affected and 3 asymptomatic mutation carriers from eight families.Results: The majority of patients presented in adulthood with motor-predominant and lower limb-predominant symptoms and the average age of onset was 31.0±15.1 years. A prominent feature was the development of proximal weakness early in the course of the disease. The disease progressed rapidly, unlike other Charcot-Marie-Tooth disease (CMT) subtypes, and half of the patients (53%) needed to use a wheelchair on average 24.1 years after symptom onset. Furthermore, 40% of patients had evidence of early ankle plantarflexion weakness, a feature which is observed in only a handful of CMT subtypes. Neurophysiological studies and MRI of the lower limbs confirmed the presence of a non-length-dependent neuropathy in the majority of patients.All families harboured heterozygous frameshift variants in the last exon of NEFH, resulting in a reading frameshift to an alternate open reading frame and the translation of approximately 42 additional amino acids from the 3' untranslated region (3'-UTR).Conclusions: This phenotype-genotype study highlights the unusual phenotype of CMT2CC, which is more akin to spinal muscular atrophy rather than classic CMT. Furthermore, the study will enable more informative discussions on the natural history of the disease and will aid in NEFH variant interpretation in the context of the disease's unique molecular genetics. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
8. New classification of autoimmune neuropathies based on target antigens and involved domains of myelinated fibres.
- Author
-
Uncini, Antonino, Mathis, Stephane, and Vallat, Jean-Michel
- Subjects
AUTOANTIBODIES ,NEUROLOGICAL disorders ,NEURONS ,AUTOIMMUNE diseases ,NEURAL conduction ,NERVE tissue ,ANTIGENS - Abstract
Autoimmune neuropathies are named by eponyms, by descriptive terminology or because of the presence of specific antibodies and are traditionally classified, on the basis of pathology and electrophysiology, as primary demyelinating or axonal. However, autoimmune disorders targeting specific molecules of the nodal region, although not showing pathological evidence of demyelination, can exhibit all the electrophysiological changes considered characteristic of a demyelinating neuropathy and acute neuropathies with antiganglioside antibodies, classified as axonal and due to nodal dysfunction, can present with reversible conduction failure and prompt recovery that appear contradictory with the common view of an axonal neuropathy. These observations bring into question the concepts of demyelinating and axonal nerve conduction changes and the groundwork of the classical dichotomous classification.We propose a classification of autoimmune neuropathies based on the involved domains of the myelinated fibre and, when known, on the antigen. This classification, in our opinion, helps to better systematise autoimmune neuropathies because points to the site and molecular target of the autoimmune attack, reconciles some contrasting pathological and electrophysiological findings, circumvents the apparent paradox that neuropathies labelled as axonal may be promptly reversible and finally avoids taxonomic confusion and possible misdiagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. IgG1 pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality.
- Author
-
Fehmi, Janev, Davies, Alexander J., Walters, Jon, Lavin, Timothy, Keh, Ryan, Rossor, Alexander M., Munteanu, Tudor, Delanty, Norman, Roberts, Rhys, Bäumer, Dirk, Lennox, Graham, and Rinaldi, Simon
- Subjects
RITUXIMAB ,CELL adhesion molecules ,INTRAVENOUS immunoglobulins ,IMMUNOGLOBULINS ,NEUROPATHY ,SENSORY neurons ,CRANIAL nerves ,DYSAUTONOMIA ,THERAPEUTIC use of immunoglobulins ,AUTOANTIBODIES ,RESEARCH ,PERIPHERAL neuropathy ,ADRENOCORTICAL hormones ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding - Abstract
Objectives: We aimed to define the clinical and serological characteristics of pan-neurofascin antibody-positive patients.Methods: We tested serum from patients with suspected immune-mediated neuropathies for antibodies directed against nodal/paranodal protein antigens using a live cell-based assay and solid-phase platform. The clinical and serological characteristics of antibody-positive and seronegative patients were then compared. Sera positive for pan-neurofascin were also tested against live myelinated human stem cell-derived sensory neurons for antibody binding.Results: Eight patients with IgG1-subclass antibodies directed against both isoforms of the nodal/paranodal cell adhesion molecule neurofascin were identified. All developed rapidly progressive tetraplegia. Cranial nerve deficits (100% vs 26%), autonomic dysfunction (75% vs 13%) and respiratory involvement (88% vs 14%) were more common than in seronegative patients. Four patients died despite treatment with one or more modalities of standard immunotherapy (intravenous immunoglobulin, steroids and/or plasmapheresis), whereas the four patients who later went on to receive the B cell-depleting therapy rituximab then began to show progressive functional improvements within weeks, became seronegative and ultimately became functionally independent.Conclusions: IgG1 pan-neurofascin antibodies define a very severe autoimmune neuropathy. We urgently recommend trials of targeted immunotherapy for this serologically classified patient group. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
10. Iatrogenic immune-mediated neuropathies: diagnostic, epidemiological and mechanistic uncertainties for causality and implications for clinical practice.
- Author
-
Goedee, H. Stephan, Attarian, Shahram, Kuntzer, Thierry, den Bergh, Peter Van, Rajabally, Yusuf A., and Van den Bergh, Peter
- Subjects
INFLUENZA ,POLYNEUROPATHIES ,MEDICAL personnel ,BRACHIAL plexus neuropathies ,SYMPTOMS ,THERAPEUTICS ,DIAGNOSIS - Abstract
Acute and chronic immune-mediated neuropathies have been widely reported with medical intervention. Although causal relationship may be uncertain in many cases, a variety of drugs, several vaccination types, surgical procedures and bone marrow transplants have been reported as possible cause or trigger of a putative immune-mediated response resulting in acute and chronic neuropathies. We conducted a systematic review of the literature from 1966 to 2020 on reported cases of possible iatrogenic immune-mediated neuropathies. We determined in each case the likelihood of causality based on frequency of the association, focusing primarily on clinical presentation and disease course as well as available ancillary investigations (electrophysiology, blood and cerebrospinal fluid and neuropathology). The response to immunotherapy and issue of re-exposure were also evaluated. We also considered hypothesised mechanisms of onset of immune-mediated neuropathy in the specific iatrogenic context. We believe that a likely causal relationship exists for only few drugs, mainly antitumour necrosis factor alpha agents and immune checkpoint inhibitors, but remains largely unsubstantiated for most other suggested iatrogenic causes. Unfortunately, given the lack of an accurate diagnostic biomarker for most immune-mediated neuropathies, clinical assessment will often override ancillary investigations, resulting in lower levels of certainty that may continue to cast serious doubts on reliability of their diagnosis. Consequently, future reports of suspected cases should collect and exhaustively assess all relevant data. At the current time, besides lack of evidence for causality, the practical implications on management of suspected cases is extremely limited and therapeutic decisions appear likely no different to those made in non-iatrogenic cases. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Chronic inflammatory demyelinating polyneuropathy and pregnancy: systematic review.
- Author
-
Kohle, Felix, Kuwabara, Satoshi, and Lehmann, Helmar Christoph
- Subjects
CHRONIC inflammatory demyelinating polyradiculoneuropathy ,PREGNANCY ,MULTIPLE pregnancy ,DURATION of pregnancy ,PREMATURE labor - Abstract
Pregnancy largely affects disease activity and clinical course in women with immune-mediated neurological disorders. Chronic inflammatory demyelinating polyneuropathy (CIDP) is rare but the most common chronic immune-mediated neuropathy; however, the effects of pregnancy on CIDP have never been investigated except case reports or series. We here provide a systematic review of the literature from 1 January 1969 to 30 June 2020 that revealed 24 women with CIDP, who had onset or relapse during pregnancy. Of these, 17 (71%) developed CIDP during the first pregnancy, and 8 (47%) had a relapse during subsequent pregnancies. Of the 17 patients, in whom the CIDP subtypes were determined, all of them had typical CIDP. First-line treatments for CIDP, such as corticosteroids, immunoglobulin and plasma exchange were efficacious and safe. We suggest that pregnancy can trigger typical CIDP in some women, and women with CIDP have a higher risk of relapse during pregnancy. The onset or relapse of CIDP during pregnancy is a rare but challenging constellation for physicians. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective.
- Author
-
Susumu Kusunoki, Willison, Hugh J., Jacobs, Bart C., and Kusunoki, Susumu
- Subjects
GUILLAIN-Barre syndrome ,IMMUNOGLOBULINS ,MOTOR neuron diseases ,CENTRAL nervous system ,ANTIBODY titer ,MILLER Fisher syndrome ,LIPIDS - Abstract
Guillain-Barré syndrome (GBS) and Fisher syndrome (FS) are acute autoimmune neuropathies, often preceded by an infection. Antiglycolipid antibody titres are frequently elevated in sera from the acute-phase patients. Particularly, IgG anti-GQ1b antibodies are positive in as high as 90% of FS cases and thus useful for diagnosis. The development of animal models of antiglycolipid antibody-mediated neuropathies proved that some of these antibodies are directly involved in the pathogenetic mechanisms by binding to the regions where the respective target glycolipid is specifically localised. Discovery of the presence of the antibodies that specifically recognise a new conformational epitope formed by two different gangliosides (ganglioside complex) in the acute-phase sera of some patients with GBS suggested the carbohydrate-carbohydrate interaction between glycolipids. This finding indicated the need for further research in basic glycobiological science. Antiglycolipid antibodies, in particular antigangliosides antibodies, are mostly detected in acute motor axonal neuropathy type of GBS and in FS, and less frequently in the acute inflammatory demyelinating polyneuropathy (AIDP) type of GBS or in central nervous system (CNS) diseases. In the future, the search for the putative antibodies in AIDP and those that might be present in CNS diseases should continue. In addition, more efficient standardisation of antiglycolipid antibody detection methods and use as biomarkers in daily clinical practice in neurology is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs.
- Author
-
Marsh, Eleanor S., Keddie, Stephen, Terris-Prestholt, Fern, D'Sa, Shirley, and Lunn, Michael P.
- Subjects
POLYNEUROPATHIES ,MONOCLONAL gammopathies ,DIAGNOSTIC errors ,NEUROPATHY ,VASCULAR endothelial growth factors ,RESEARCH ,RESEARCH methodology ,POEMS syndrome ,COST control ,MEDICAL care costs ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,COST effectiveness ,EARLY diagnosis - Abstract
Background: Prompt diagnosis and early treatment prevents disability in Polyneuropathy Organomegaly Endocrinopathy Monoclonal-protein and Skin Changes (POEMS) syndrome. Delay in diagnosis is common with 55% of patients initially incorrectly diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Patients are often treated with intravenous immunoglobulin which is both expensive and ineffective in the treatment of POEMS. Testing patients with acquired demyelinating neuropathy with serum vascular endothelial growth factor (VEGF) more accurately identifies POEMS syndrome than the current standard of care. Incorporating VEGF testing into screening could prevent misdiagnosis and reduce costs.Methods: We used observed treatment information for patients in the University College London Hospital's POEMS syndrome database (n=100) and from the National Immunoglobulin Database to estimate costs associated with incorrect CIDP diagnoses across our cohort. We conducted a model-based cost-effectiveness analysis to compare the current diagnostic algorithm with an alternative which includes VEGF testing for all patients with an acquired demyelinating neuropathy.Results: Treatment associated with an incorrect CIDP diagnosis led to total wasted healthcare expenditures of between £808 550 and £1 111 756 across our cohort, with an average cost-per-POEMS-patient misdiagnosed of £14 701 to £20 214. Introducing mandatory VEGF testing for patients with acquired demyelinating neuropathy would lead to annual cost-savings of £107 398 for the National Health Service and could prevent misdiagnosis in 16 cases per annum.Conclusions: Misdiagnosis in POEMS syndrome results in diagnostic delay, disease progression and significant healthcare costs. Introducing mandatory VEGF testing for patients with acquired demyelinating neuropathy is a cost-effective strategy allowing for early POEMS diagnosis and potentially enabling prompt disease-directed therapy. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
14. Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome.
- Author
-
Yuko Yamagishi, Motoi Kuwahara, Hidekazu Suzuki, Masahiro Sonoo, Satoshi Kuwabara, Takanori Yokota, Kyoichi Nomura, Atsuro Chiba, Ryuji Kaji, Takashi Kanda, Ken-ichi Kaida, Tatsuro Mutoh, Ryo Yamasaki, Hiroshi Takashima, Makoto Matsui, Kazutoshi Nishiyama, Gen Sobue, Susumu Kusunoki, Yamagishi, Yuko, and Kuwahara, Motoi
- Subjects
GUILLAIN-Barre syndrome ,SERUM ,IMMUNOGLOBULINS ,GANGLIOSIDES ,SYMPTOMS ,TREATMENT of Guillain-Barre syndrome ,AUTOANTIBODIES ,ELECTRODIAGNOSIS ,DIARRHEA ,AGE distribution ,PROGNOSIS ,RETROSPECTIVE studies ,ARTIFICIAL respiration ,LIPIDS - Abstract
Objective: Approximately 15%-20% of patients with Guillain-Barré syndrome (GBS) are unable to walk independently at 6 months from the onset of neurological symptom. The modified Erasmus GBS outcome score (mEGOS) has been reported as a prognostic tool.Herein we investigated the association between a poor outcome, inability to walk independently at 6 months and presence of antiganglioside antibodies.Methods: The clinical and serological data of 177 patients with GBS were retrospectively collected in Japan to assess the associations between a poor outcome and serum IgG antibodies against each ganglioside (GM1, GD1a, GalNAc-GD1a, GQ1b and GT1a). In addition, we investigated whether the combination of mEGOS and serum IgG antibodies against gangliosides is useful in predicting a poor outcome.Results: The patients with IgG anti-GD1a antibodies more frequently showed poor outcomes than those without these antibodies (9 (36%) of 25 vs 8 (6%) of 127 patients, p<0.001). Particularly, 80% showed a poor outcome when they had both serum IgG anti-GD1a antibody and a high mEGOS of ≥10 on day 7 of admission.Conclusions: The combination of serum IgG anti-GD1a antibodies and a high mEGOS could help in making a more accurate prognosis of patients than mEGOS alone, especially for predicting poor outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
15. Multifocal motor neuropathy: controversies and priorities.
- Author
-
Wei Zhen Yeh, Dyck, P James, van den Berg, Leonard H., Kiernan, Matthew C., Taylor, Bruce V., and Yeh, Wei Zhen
- Subjects
MOTOR neuron diseases ,PERIPHERAL nervous system ,SPINAL muscular atrophy ,CENTRAL nervous system ,AMYOTROPHIC lateral sclerosis ,DIFFERENTIAL diagnosis ,MAGNETIC resonance imaging ,POLYNEUROPATHIES ,ULTRASONIC imaging - Abstract
Despite 30 years of research there are still significant unknowns and controversies associated with multifocal motor neuropathy (MMN) including disease pathophysiology, diagnostic criteria and treatment. Foremost relates to the underlying pathophysiology, specifically whether MMN represents an axonal or demyelinating neuropathy and whether the underlying pathophysiology is focused at the node of Ranvier. In turn, this discussion promotes consideration of therapeutic approaches, an issue that becomes more directed in this evolving era of precision medicine. It is generally accepted that MMN represents a chronic progressive immune-mediated motor neuropathy clinically characterised by progressive asymmetric weakness and electrophysiologically by partial motor conduction block. Anti-GM1 IgM antibodies are identified in at least 40% of patients. There have been recent developments in the use of neuromuscular ultrasound and MRI to aid in diagnosing MMN and in further elucidation of its pathophysiological mechanisms. The present Review will critically analyse the knowledge accumulated about MMN over the past 30 years, culminating in a state-of-the-art approach to therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Clinical characterisation of sensory neuropathy with anti-FGFR3 autoantibodies.
- Author
-
Tholance, Yannick, Moritz, Christian Peter, Rosier, Carole, Ferraud, Karine, Lassablière, François, Reynaud-Federspiel, Evelyne, França Jr, Marcondes C., Martinez, Alberto R. M., Camdessanché, Jean-Philippe, Antoine, Jean-Christophe, França, Marcondes C Jr, and anti-FGFR3 antibody Study Group
- Subjects
AUTOANTIBODIES ,FIBROBLAST growth factor receptors ,NEUROPATHY ,AUTOANTIBODY analysis ,ELECTRODIAGNOSIS ,RESEARCH ,NEURONS ,RESEARCH methodology ,CELL receptors ,EVALUATION research ,MEDICAL cooperation ,COMPARATIVE studies ,CHARCOT-Marie-Tooth disease ,RESEARCH funding ,LONGITUDINAL method - Abstract
Objective: Sensory neuropathies (SNs) are often classified as idiopathic even if immunological mechanisms can be suspected. Antibodies against the intracellular domain of the fibroblast growth factor receptor 3 (FGFR3) possibly identify a subgroup of SN affecting mostly the dorsal root ganglion (DRG). The aim of this study was to identify the frequency of anti-FGFR3 antibodies and the associated clinical pattern in a large cohort of patients with SN.Methods: A prospective, multicentric, European and Brazilian study included adults with pure SN. Serum anti-FGRF3 antibodies were analysed by ELISA. Detailed clinical and paraclinical data were collected for each anti-FGFR3-positive patient and as control for anti-FGFR3-negative patients from the same centres ('center-matched').Results: Sixty-five patients out of 426 (15%) had anti-FGFR3 antibodies, which were the only identified autoimmune markers in 43 patients (66%). The neuropathy was non-length dependent in 89% and classified as sensory neuronopathy in 64%, non-length-dependent small fibre neuropathy in 17% and other neuropathy in 19%. Specific clinical features occurred after 5-6 years of evolution including frequent paresthesia, predominant clinical and electrophysiological involvement of the lower limbs, and a less frequent mixed large and small fibre involvement. Brazilians had a higher frequency of anti-FGFR3 antibodies than Europeans (36% vs 13%, p<0.001), and a more frequent asymmetrical distribution of symptoms (OR 169, 95% CI 3.4 to 8424).Conclusions: Anti-FGFR3 antibodies occur in a subgroup of SN probably predominantly affecting the DRG. Differences between Europeans and Brazilians could suggest involvement of genetic or environmental factors. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
17. Beware next-generation sequencing gene panels as the first-line genetic test in Charcot-Marie-Tooth disease.
- Author
-
Record, Christopher J., Pipis, Menelaos, Poh, Roy, Polke, James M., and Reilly, Mary M.
- Subjects
CHARCOT-Marie-Tooth disease ,MYASTHENIA gravis ,GENETIC testing ,NUCLEOTIDE sequencing ,MEDICAL care - Published
- 2023
- Full Text
- View/download PDF
18. Development of MRC Centre MRI calf muscle fat fraction protocol as a sensitive outcome measure in Hereditary Sensory Neuropathy Type 1.
- Author
-
Kugathasan, Umaiyal, Evans, Matthew R. B., Morrow, Jasper M., Sinclair, Christopher D. J., Thornton, John S., Yousry, Tarek A., Hornemann, Thorsten, Suriyanarayanan, Saranya, Owusu-Ansah, Khadijah, Lauria, Giuseppe, Lombardi, Raffaella, Polke, James M., Wilson, Emma, Bennett, David L. H., Houlden, Henry, Hanna, Michael G., Blake, Julian C., Laura, Matilde, and Reilly, Mary M.
- Subjects
CALF muscles ,LEBER'S hereditary optic atrophy ,NEUROPATHY - Abstract
Objectives: Hereditary sensory neuropathy type 1 (HSN1) is a rare, slowly progressive neuropathy causing profound sensory deficits and often severe motor loss. L-serine supplementation is a possible candidate therapy but the lack of responsive outcome measures is a barrier for undertaking clinical trials in HSN1. We performed a 12-month natural history study to characterise the phenotype of HSN1 and to identify responsive outcome measures.Methods: Assessments included Charcot-Marie-Tooth Neuropathy Score version 2 (CMTNSv2), CMTNSv2-Rasch modified, nerve conduction studies, quantitative sensory testing, intraepidermal nerve fibre density (thigh), computerised myometry (lower limbs), plasma 1-deoxysphingolipid levels, calf-level intramuscular fat accumulation by MRI and patient-based questionnaires (Neuropathic Pain Symptom Inventory and 36-Short Form Health Survey version 2 [SF-36v2]).Results: 35 patients with HSN1 were recruited. There was marked heterogeneity in the phenotype mainly due to differences between the sexes: males generally more severely affected. The outcome measures that significantly changed over 1 year and correlated with CMTNSv2, SF-36v2-physical component and disease duration were MRI determined calf intramuscular fat accumulation (mean change in overall calf fat fraction 2.36%, 95% CI 1.16 to 3.55, p=0.0004), pressure pain threshold on the hand (mean change 40 kPa, 95% CI 0.7 to 80, p=0.046) and myometric measurements of ankle plantar flexion (median change -0.5 Nm, IQR -9.5 to 0, p=0.0007), ankle inversion (mean change -0.89 Nm, 95% CI -1.66 to -0.12, p=0.03) and eversion (mean change -1.61 Nm, 95% CI -2.72 to -0.51, p=0.006). Intramuscular calf fat fraction was the most responsive outcome measure.Conclusion: MRI determined calf muscle fat fraction shows validity and high responsiveness over 12 months and will be useful in HSN1 clinical trials. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
19. Increased IP-10 production by blood-nerve barrier in multifocal acquired demyelinating sensory and motor neuropathy and multifocal motor neuropathy.
- Author
-
Fumitaka Shimizu, Mariko Oishi, Setsu Sawai, Minako Beppu, Sonoko Misawa, Naoko Matsui, Ai Miyashiro, Toshihiko Maeda, Yukio Takeshita, Hideaki Nishihara, Yasuteru Sano, Ryota Sato, Ryuji Kaji, Satoshi Kuwabara, Takashi Kanda, Shimizu, Fumitaka, Oishi, Mariko, Sawai, Setsu, Beppu, Minako, and Misawa, Sonoko
- Subjects
MYELIN oligodendrocyte glycoprotein ,MEDICAL sciences ,SPINAL muscular atrophy ,NEUROPATHY ,MACROPHAGE inflammatory proteins - Abstract
Objective: Dysfunction of the blood-nerve barrier (BNB) plays important roles in chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). The aim of the present study was to identify the candidate cytokines/chemokines that cause the breakdown of the BNB using sera from patients with CIDP and MMN.Methods: We determined the levels of 27 cytokines and chemokines in human peripheral nerve microvascular endothelial cells (PnMECs) after exposure to sera obtained from patients with CIDP variants (typical CIDP and multifocal acquired demyelinating sensory and motor neuropathy [MADSAM]), MMN and amyotrophic lateral sclerosis (ALS), and healthy controls (HC), using a multiplexed fluorescent bead-based immunoassay system.Results: The induced protein (IP)10 level in the cells in both the MADSAM and MMN groups was markedly increased in comparison with the typical CIDP, ALS and HC groups. The other cytokines, including granulocyte colony-stimulating factor,vascular endothelial growth factor (VEGF) and interleukin-7, were also significantly upregulated in the MADSAM group. The increase of IP-10 produced by PnMECs was correlated with the presence of conduction block in both the MADSAM and MMN groups.Conclusion: The autocrine secretion of IP-10 induced by patient sera in PnMECs was markedly upregulated in both the MADSAM and MMN groups. The overproduction of IP-10 by PnMECs leads to the focal breakdown of the BNB and may help to mediate the transfer of pathogenic T cells across the BNB, thereby resulting in the appearance of conduction block in electrophysiological studies of patients with MADSAM and MMN. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
20. Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development.
- Author
-
Juneja, Manisha, Burns, Joshua, Saporta, Mario A., and Timmerman, Vincent
- Subjects
MOLECULAR genetics ,MEDICAL model ,ANIMAL models in research - Abstract
Much has been achieved in terms of understanding the complex clinical and genetic heterogeneity of Charcot-Marie-Tooth neuropathy (CMT). Since the identification of mutations in the first CMT associated gene, PMP22, the technological advancement in molecular genetics and gene technology has allowed scientists to generate diverse animal models expressing monogenetic mutations that closely resemble the CMT phenotype. Additionally, one can now culture patient-derived neurons in a dish using cellular reprogramming and differentiation techniques. Nevertheless, despite the fact that finding a disease-causing mutation offers a precise diagnosis, there is no cure for CMT at present. This review will shed light on the exciting advancement in CMT disease modelling, the breakthroughs, pitfalls, current challenges for scientists and key considerations to move the field forward towards successful therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
21. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis
- Author
-
Antonia Carroll, P James Dyck, Mamede de Carvalho, Marina Kennerson, Mary M Reilly, Matthew C Kiernan, Steve Vucic, and Repositório da Universidade de Lisboa
- Subjects
Amyloid Neuropathies, Familial ,Polyneuropathies ,Amyloid ,Psychiatry and Mental health ,Heart Diseases ,Quality of Life ,Humans ,Prealbumin ,Surgery ,Neurology (clinical) ,Neuropathy - Abstract
© Author(s) (or their employer(s)) 2022. Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0, Hereditary transthyretin amyloidosis (ATTRv) is a severe, adult-onset autosomal dominant inherited systemic disease predominantly affecting the peripheral and autonomic nervous system, heart, kidney and the eyes. ATTRv is caused by mutations of the transthyretin (TTR) gene, leading to extracellular deposition of amyloid fibrils in multiple organs including the peripheral nervous system. Typically, the neuropathy associated with ATTRv is characterised by a rapidly progressive and disabling sensorimotor axonal neuropathy with early small-fibre involvement. Carpal tunnel syndrome and cardiac dysfunction frequently coexist as part of the ATTRv phenotype. Although awareness of ATTRv polyneuropathy among neurologists has increased, the rate of misdiagnosis remains high, resulting in significant diagnostic delays and accrued disability. A timely and definitive diagnosis is important, given the emergence of effective therapies which have revolutionised the management of transthyretin amyloidosis. TTR protein stabilisers diflunisal and tafamidis can delay the progression of the disease, if treated early in the course. Additionally, TTR gene silencing medications, patisiran and inotersen, have resulted in up to 80% reduction in TTR production, leading to stabilisation or slight improvement of peripheral neuropathy and cardiac dysfunction, as well as improvement in quality of life and functional outcomes. The considerable therapeutic advances have raised additional challenges, including optimisation of diagnostic techniques and management approaches in ATTRv neuropathy. This review highlights the key advances in the diagnostic techniques, current and emerging management strategies, and biomarker development for disease progression in ATTRv., SV gratefully acknowledges funding support from the National Health and Medical Research Council (NHMRC) of Australia (project grant numbers 510233, 1024915 and 1055778; program grant number 1132524; dementia research team grant number 1095127; and Partnership Project number 1153439) and the Motor Neuron Disease Research Institute of Australia. MCK was supported by a NHMRC Practitioner Fellowship (number 1156093).
- Published
- 2022
22. Neurofascin-155 IgM autoantibodies in patients with inflammatory neuropathies.
- Author
-
Doppler, Kathrin, Stengel, Helena, Appeltshauser, Luise, Grosskreutz, Julian, Man Ng, Judy King, Meinl, Edgar, and Sommer, Claudia
- Subjects
NEUROPATHY ,IMMUNOGLOBULIN M ,AUTOANTIBODIES ,DEMYELINATION ,ENZYME-linked immunosorbent assay ,WESTERN immunoblotting ,THERAPEUTICS ,CELL adhesion molecules ,COMPARATIVE studies ,GLYCOPROTEINS ,IMMUNOGLOBULINS ,RESEARCH methodology ,MEDICAL cooperation ,NERVE growth factor ,GUILLAIN-Barre syndrome ,RESEARCH ,EVALUATION research - Abstract
Objectives: Recently, IgG autoantibodies against different paranodal proteins have been detected and this has led to important advances in the management of inflammatory neuropathies. In contrast, not much is known on IgM autoantibodies against paranodal proteins.Methods: In the present study, we screened a large cohort of patients (n=140) with inflammatory neuropathies for IgM autoantibodies against neurofascin-155, neurofascin-186 or contactin-1.Results: IgM autoantibodies against neurofascin-155 were detected by ELISA in five patients, four with inflammatory demyelinating polyradiculoneuropathy (CIDP) and one with Guillain-Barré syndrome (GBS), and were confirmed by ELISA-based preabsorption experiments and Western blot. Titres ranged from 1:100 to 1:400. We did not detect IgM anti-neurofascin-186 or anti-contactin-1 antibodies in this cohort. All patients presented with distally accentuated tetraparesis and hypesthesia. Remarkably, tremor was present in three of the patients with CIDP and occurred in the patients with GBS after the acute phase of disease. Nerve conduction studies revealed prolonged distal motor latencies and F wave latencies. Nerve biopsies showed signs of secondary axonal damage in three of the patients, demyelinating features in one patient. Teased fibre preparations did not demonstrate paranodal damage.Conclusion: In summary, IgM neurofascin-155 autoantibodies may be worth testing in patients with inflammatory neuropathies. Their pathogenic role needs to be determined in future experiments. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
23. Validation of the 2021 EAN/PNS diagnostic criteria for chronic inflammatory demyelinating polyneuropathy.
- Author
-
Satoshi Kuwabara, Tomoki Suichi, Kuwabara, Satoshi, and Suichi, Tomoki
- Subjects
RESEARCH evaluation ,GUILLAIN-Barre syndrome - Published
- 2022
- Full Text
- View/download PDF
24. Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies.
- Author
-
Fargeot, Guillaume, Dupel-Pottier, Corinne, Stephant, Maeva, Lazarovici, Julien, Thomas, Laure, Mouthon-Reignier, Capucine, Riad, Benramdane, Carde, Patrice, Berzero, Giulia, Tafani, Camille, Nicolas, Weiss, Viala, Karine, Maisonobe, Thierry, Lenglet, Timothée, Wang, Adrien, Magy, Laurent, Bihan, Kevin, Gaspar, Nathalie, Adams, David, and Echaniz-Laguna, Andoni
- Subjects
HODGKIN'S disease ,MOTOR neuron diseases - Published
- 2020
- Full Text
- View/download PDF
25. Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG.
- Author
-
Jitprapaikulsan, Jiraporn, Klein, C. J., Pittock, Sean J., Gadoth, Avi, McKeon, Andrew, Mills, John R., and Dubey, Divyanshu
- Subjects
PARANEOPLASTIC syndromes ,SMALL cell lung cancer ,ENTERIC nervous system ,DORSAL root ganglia - Published
- 2020
- Full Text
- View/download PDF
26. PFN2 and GAMT as common molecular determinants of axonal Charcot-Marie-Tooth disease.
- Author
-
Juneja, Manisha, Azmi, Abdelkrim, Baets, Jonathan, Roos, Andreas, Jennings, Matthew J., Saveri, Paola, Pisciotta, Chiara, Bernard-Marissal, Nathalie, Schneider, Bernard L., Verfaillie, Catherine, Chrast, Roman, Seeman, Pavel, Hahn, Angelika F., de Jonghe, Peter, Maudsley, Stuart, Horvath, Rita, Pareyson, Davide, and Timmerman, Vincent
- Subjects
CHARCOT-Marie-Tooth disease ,NEUROPATHY ,LYMPHOBLASTIC leukemia ,GENETIC mutation ,PLURIPOTENT stem cells ,PATIENTS - Abstract
Background: Charcot-Marie-Tooth type 2 (CMT2) neuropathy is characterised by a vast clinical and genetic heterogeneity complicating its diagnosis and therapeutic intervention. Identification of molecular signatures that are common to multiple CMT2 subtypes can aid in developing therapeutic strategies and measuring disease outcomes.Methods: A proteomics-based approach was performed on lymphoblasts from CMT2 patients genetically diagnosed with different gene mutations to identify differentially regulated proteins. The candidate proteins were validated through real-time quantitative PCR and western blotting on lymphoblast samples of patients and controls, motor neurons differentiated from patient-derived induced pluripotent stem cells (iPSCs) and sciatic nerves of CMT2 mouse models.Results: Proteomic profiling of patient lymphoblasts resulted in the identification of profilin 2 (PFN2) and guanidinoacetate methyltransferase (GAMT) as commonly downregulated proteins in different genotypes compared with healthy controls. This decrease was also observed at the transcriptional level on screening 43 CMT2 patients and 22 controls, respectively. A progressive decrease in PFN2 expression with age was observed in patients, while in healthy controls its expression increased with age. Reduced PFN2 expression was also observed in motor neurons differentiated from CMT2 patient-derived iPSCs and sciatic nerves of CMT2 mice when compared with controls. However, no change in GAMT levels was observed in motor neurons and CMT2 mouse-derived sciatic nerves.Conclusions: We unveil PFN2 and GAMT as molecular determinants of CMT2 with possible indications of the role of PFN2 in the pathogenesis and disease progression. This is the first study describing biomarkers that can boost the development of therapeutic strategies targeting a wider spectrum of CMT2 patients. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
27. Quality of life in inflammatory neuropathies: the IN-QoL.
- Author
-
Draak, Thomas H. P., Faber, Catharina G., Merkies, Ingemar S. J., and PeriNomS study Group
- Subjects
NEUROPATHY ,GUILLAIN-Barre syndrome ,MONOCLONAL gammopathies ,QUALITY of life ,POLYNEUROPATHIES ,RESEARCH ,FERRANS & Powers Quality of Life Index ,PERIPHERAL neuropathy ,PARAPROTEINEMIA ,RESEARCH evaluation ,RESEARCH methodology ,VISUAL analog scale ,EVALUATION research ,MEDICAL cooperation ,MULTIDIMENSIONAL Health Locus of Control scales ,COMPARATIVE studies ,FACTOR analysis ,DISEASE complications - Abstract
Background: No consensus exists which quality of life (QoL) measure should be used in patients with inflammatory neuropathies. Moreover, most QoL measures are ordinal-based scales with their known deficiencies.Objectives: To establish a new disease-specific interval-based QoL questionnaire in inflammatory neuropathies (IN-QoL) using the Rasch model and evaluate its scientific properties (validity, reliability and responsiveness).Methods: 264 patients with inflammatory neuropathies completed six commonly used QoL questionnaires. The obtained data were stacked and subjected to Rasch analysis. Responsiveness was determined by using the concept of minimum clinically important differences related to varying individually obtained SEs (responsiveness definition: MCID-SE≥1.96 after 1-year follow-up compared with baseline).Results: The IN-QoL fulfilled all Rasch's model requirements with high internal reliability values (patient separation index of 0.94), except being multidimensional. Additional factor analysis resulted in two (functional and mental) subsets that were unidimensional on their own. The IN-QoL showed good correlation with the EuroQol-health quality visual analogue scale (EQ-VAS) (Spearman's rho 0.72). It demonstrated acceptable responsiveness in patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), as did the EQ-VAS. In patients with monoclonal gammopathy-related neuropathy and multifocal motor neuropathy, hardly any changes were seen over time.Conclusion: The IN-QoL questionnaire fulfils modern clinimetric requirements and correlates strongly with a patient's self-assessment of their own quality of health, while also showing responsiveness in patients with GBS and CIDP. We propose using the IN-QoL and the EQ-VAS for assessing the QoL of patients with inflammatory neuropathies in future studies. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
28. Controversy of posterior reversible encephalopathy syndrome: what have we learnt in the last 20 years?
- Author
-
Bo Gao, Cui Lyu, Lerner, Alexander, and McKinney, Alexander M.
- Subjects
CEREBROVASCULAR disease ,NEUROLOGICAL disorders ,NEUROPATHY ,HYPERTENSIVE encephalopathy ,NERVOUS system - Published
- 2018
- Full Text
- View/download PDF
29. IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy.
- Author
-
Campagnolo, Marta, Zambello, Renato, Nobile-Orazio, Eduardo, Benedetti, Luana, Marfia, Girolama Alessandra, Riva, Nilo, Castellani, Francesca, Bianco, Mariangela, Salvalaggio, Alessandro, Garnero, Martina, Ruiz, Marta, Mataluni, Giorgia, Fazio, Raffaella, Ermani, Mario, and Briani, Chiara
- Subjects
RITUXIMAB ,NEUROPATHY ,WALDENSTROM'S macroglobulinemia ,GLYCOPROTEINS ,LYMPHOPROLIFERATIVE disorders - Published
- 2017
- Full Text
- View/download PDF
30. Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A.
- Author
-
Fledrich, Robert, Mannil, Manoj, Leha, Andreas, Ehbrecht, Caroline, Solari, Alessandra, Pelayo-Negro, Ana L., Berciano, José, Schlotter-Weigel, Beate, Schnizer, Tuuli J., Prukop, Thomas, Garcia-Angarita, Natalia, Czesnik, Dirk, Haberlová, Jana, Mazanec, Radim, Paulus, Walter, Beissbarth, Tim, Walter, Maggie C., CMT-TRIAAL, Hogrel, Jean-Yves, and Dubourg, Odile
- Subjects
CHARCOT-Marie-Tooth disease ,BIOMARKERS ,NEUROPATHY ,MESSENGER RNA ,SKIN biopsy - Abstract
Background: Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common inherited neuropathy, a debilitating disease without known cure. Among patients with CMT1A, disease manifestation, progression and severity are strikingly variable, which poses major challenges for the development of new therapies. Hence, there is a strong need for sensitive outcome measures such as disease and progression biomarkers, which would add powerful tools to monitor therapeutic effects in CMT1A.Methods: We established a pan-European and American consortium comprising nine clinical centres including 311 patients with CMT1A in total. From all patients, the CMT neuropathy score and secondary outcome measures were obtained and a skin biopsy collected. In order to assess and validate disease severity and progression biomarkers, we performed qPCR on a set of 16 animal model-derived potential biomarkers in skin biopsy mRNA extracts.Results: In 266 patients with CMT1A, a cluster of eight cutaneous transcripts differentiates disease severity with a sensitivity and specificity of 90% and 76.1%, respectively. In an additional cohort of 45 patients with CMT1A, from whom a second skin biopsy was taken after 2-3 years, the cutaneous mRNA expression of GSTT2, CTSA, PPARG, CDA, ENPP1 and NRG1-Iis changing over time and correlates with disease progression.Conclusions: In summary, we provide evidence that cutaneous transcripts in patients with CMT1A serve as disease severity and progression biomarkers and, if implemented into clinical trials, they could markedly accelerate the development of a therapy for CMT1A. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
31. Peripheral neuropathy in complex inherited diseases: an approach to diagnosis.
- Author
-
Rossor, Alexander M., Carr, Aisling S., Devine, Helen, Chandrashekar, Hoskote, Pelayo-Negro, Ana Lara, Pareyson, Davide, Shy, Michael E., Scherer, Steven S., and Reilly, Mary M.
- Subjects
GENETIC disorder diagnosis ,PERIPHERAL neuropathy diagnosis ,SPASTICITY ,DIAGNOSIS of neurological disorders ,GUILLAIN-Barre syndrome - Abstract
Peripheral neuropathy is a common finding in patients with complex inherited neurological diseases and may be subclinical or a major component of the phenotype. This review aims to provide a clinical approach to the diagnosis of this complex group of patients by addressing key questions including the predominant neurological syndrome associated with the neuropathy, for example, spasticity, the type of neuropathy and the other neurological and non-neurological features of the syndrome. Priority is given to the diagnosis of treatable conditions. Using this approach, we associated neuropathy with one of three major syndromic categories: (1) ataxia, (2) spasticity and (3) global neurodevelopmental impairment. Syndromes that do not fall easily into one of these three categories can be grouped according to the predominant system involved in addition to the neuropathy, for example, cardiomyopathy and neuropathy. We also include a separate category of complex inherited relapsing neuropathy syndromes, some of which may mimic Guillain-Barré syndrome, as many will have a metabolic aetiology and be potentially treatable. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
32. Expanding the spectrum of VEXAS syndrome: association with acute-onset CIDP.
- Author
-
Bert-Marcaz, Charlotte, Briantais, Antoine, Faucher, Benoit, Corazza, Giovanni, Ebbo, Mikael, Attarian, Shahram, Delmont, Emilien, and Fortanier, Etienne
- Subjects
NEURAL conduction ,GUILLAIN-Barre syndrome ,DISEASE complications - Published
- 2022
- Full Text
- View/download PDF
33. Genetic and clinical characteristics of -related Charcot-Marie-Tooth disease.
- Author
-
Horga, Alejandro, Laurà, Matilde, Jaunmuktane, Zane, Jerath, Nivedita U., Gonzalez, Michael A., Polke, James M., Poh, Roy, Blake, Julian C., Yo-Tsen Liu, Wiethoff, Sarah, Bettencourt, Conceição, Lunn, Michael P. T., Manji, Hadi, Hanna, Michael G., Houlden, Henry, Brandner, Sebastian, Züchner, Stephan, Shy, Michael, Reilly, Mary M., and Liu, Yo-Tsen
- Subjects
CHARCOT-Marie-Tooth disease ,GENETIC disorders ,MYELIN sheath ,NUCLEOTIDE sequencing ,HUMAN genetic variation ,NEUROPATHY ,CEREBELLAR ataxia ,GENEALOGY ,GENETIC techniques ,GENETIC mutation ,NERVE tissue proteins ,NEURONS ,RESEARCH funding ,TIBIAL nerve ,PHENOTYPES ,GENOTYPES - Abstract
Objectives: To analyse and describe the clinical and genetic spectrum of Charcot-Marie-Tooth disease (CMT) caused by mutations in the neurofilament light polypeptide gene (NEFL).Methods: Combined analysis of newly identified patients with NEFL-related CMT and all previously reported cases from the literature.Results: Five new unrelated patients with CMT carrying the NEFL mutations P8R and N98S and the novel variant L311P were identified. Combined data from these cases and 62 kindreds from the literature revealed four common mutations (P8R, P22S, N98S and E396K) and three mutational hotspots accounting for 37 (55%) and 50 (75%) kindreds, respectively. Eight patients had de novo mutations. Loss of large-myelinated fibres was a uniform feature in a total of 21 sural nerve biopsies and 'onion bulb' formations and/or thin myelin sheaths were observed in 14 (67%) of them. The neurophysiological phenotype was broad but most patients with E90K and N98S had upper limb motor conduction velocities <38 m/s. Age of onset was ≤3 years in 25 cases. Pyramidal tract signs were described in 13 patients and 7 patients were initially diagnosed with or tested for inherited ataxia. Patients with E90K and N98S frequently presented before age 3 years and developed hearing loss or other neurological features including ataxia and/or cerebellar atrophy on brain MRI.Conclusions: NEFL-related CMT is clinically and genetically heterogeneous. Based on this study, however, we propose mutational hotspots and relevant clinical-genetic associations that may be helpful in the evaluation of NEFL sequence variants and the differential diagnosis with other forms of CMT. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
34. Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis.
- Author
-
Tackley, George, Vecchio, Domizia, Hamid, Shahd, Jurynczyk, Maciej, Yazhuo Kong, Gore, Rosie, Mutch, Kerry, Woodhall, Mark, Waters,, Patrick, Vincent, Angela, Leite, Maria Isabel, Tracey, Irene, Jacob, Anu, Palace, Jacqueline, and Kong, Yazhuo
- Subjects
TISSUE wounds ,AQUAPORINS ,NEUROPATHY ,MYELITIS ,PAIN - Abstract
Importance: Chronic, intractable neuropathic pain is a common and debilitating consequence of neuromyelitis optica spectrum disorder (NMOSD) myelitis, with no satisfactory treatment; few studies have yet to explore its aetiology.Objective: To establish if myelitis-associated chronic pain in NMOSD is related to the craniocaudal location of spinal cord lesions.Method: (1) Retrospective cohort of 76 aquaporin 4-antibody (AQP4-Ab)-positive patients from Oxford and Liverpool's national NMOSD clinics, assessing current pain and craniocaudal location of cord lesion contemporary to pain onset. (2) Focused prospective study of 26 AQP4-Ab-positive Oxford patients, a subset of the retrospective cohort, assessing current craniocaudal lesion location and current pain.Results: Patients with isolated thoracic cord myelitis at the time of pain onset were significantly more disabled and suffered more pain. Cervical and thoracic lesions that persisted from pain onset to 'out of relapse' follow-up (current MRI) had highly significant (p<0.01) opposing effects on pain scores (std. β=-0.46 and 0.48, respectively). Lesion length, total lesion burden and number of transverse myelitis relapses did not correlate with pain.Conclusions: Persistent, caudally located (ie, thoracic) cord lesions in AQP4-Ab-positive patients associate with high postmyelitis chronic pain scores, irrespective of number of myelitis relapses, lesion length and lesion burden. Although disability correlated with pain in isolation, it became an insignificant predictor of pain when analysed alongside craniocaudal location of lesions. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
35. Metabolic syndrome is related to polyneuropathy and impaired peripheral nerve function: a prospective population-based cohort study.
- Author
-
Hanewinckel, Rens, Drenthen, Judith, Ligthart, Symen, Dehghan, Abbas, Franco, Oscar H., Hofman, Albert, Ikram, M. Arfan, and van Doorn, Pieter A.
- Subjects
METABOLIC syndrome treatment ,NEUROPATHY ,DIABETES risk factors ,PERIPHERAL nerve injuries ,COHORT analysis - Abstract
Objective: Diabetes mellitus is a known risk factor for polyneuropathy, but the role of pre-diabetes and metabolic syndrome remains unclear. We aimed to investigate the role of these factors in a community-dwelling middle-aged and elderly population.Methods: 1256 participants of the population-based Rotterdam Study (mean age 70.0, 54.5% females) were screened for polyneuropathy with a questionnaire, neurological examination and nerve conduction studies. Data on type 2 diabetes and components of metabolic syndrome were also collected. Logistic regression was used to investigate associations of diabetes, pre-diabetes and metabolic syndrome and its separate components with polyneuropathy. Linear regression was used to investigate associations with nerve conduction parameters in participants without polyneuropathy.Findings: Diabetes was associated with polyneuropathy (OR 3.01, 95% CI 1.60 to 5.65), while impaired fasting glucose was not (OR 1.55, 95% CI 0.70 to 3.44). Metabolic syndrome was associated with polyneuropathy (OR 1.92, 95% CI 1.09 to 3.38), with a stronger association when more components of the syndrome were present. Analysing separate components of metabolic syndrome revealed associations for elevated waist circumference (OR 2.84, 95% CI 1.35 to 5.99) and elevated triglycerides (OR 2.01, 95% CI 1.11 to 3.62). Similar associations were found after excluding participants with diabetes. In participants without polyneuropathy, metabolic syndrome associated with lower sural sensory nerve action potential amplitudes.Conclusions: Metabolic syndrome, abdominal obesity and dyslipidaemia, are strongly associated with polyneuropathy, irrespective of the presence of diabetes. Metabolic syndrome also associates with impaired nerve function in people without polyneuropathy. Our study therefore suggests that cardiometabolic disturbances have an impact on peripheral nerve function that extends beyond clinically manifest disease. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
36. Phenotype and natural history of inherited neuropathies caused by HSJ1 c.352+1G>A mutation.
- Author
-
Frasquet, M., Chumillas, M. J., Vílchez, J. J., Márquez-Infante, C., Palau, F., Vázquez-Costa, J. F., Lupo, V., Espinós, C., and Sevilla, T.
- Subjects
NEUROPATHY ,GENETIC mutation ,PHENOTYPES ,HISTORY of medicine ,TERTIARY care ,PATIENTS ,CARRIER proteins ,CHARCOT-Marie-Tooth disease ,COMPARATIVE studies ,HEAT shock proteins ,RESEARCH methodology ,MEDICAL cooperation ,NEURAL conduction ,RESEARCH ,EVALUATION research ,NUCLEAR proteins ,CELL cycle proteins - Published
- 2016
- Full Text
- View/download PDF
37. Hereditary and inflammatory neuropathies: a review of reported associations, mimics and misdiagnoses.
- Author
-
Rajabally, Yusuf A., Adams, David, Latour, Philippe, and Attarian, Shahram
- Subjects
NEUROPATHY ,IMMUNOTHERAPY ,GENETIC counseling ,CHARCOT-Marie-Tooth disease ,MOLECULAR diagnosis - Abstract
Distinguishing between hereditary and inflammatory neuropathy is usually straightforward on clinical grounds with the help of a family history. There are nevertheless cases where the distinction is less clear. The advent of molecular genetics has in the past several years aided confirmatory diagnosis for an increasing proportion of patients with genetic neuropathy. Various reports have described associations of Charcot-Marie-Tooth disease with a suspected or confirmed inflammatory neuropathy occasionally responding to immunotherapy. Possible predisposition to an inflammatory component was suggested in a subset of patients. Such reports have, however, been relatively few in number, suggesting the rarity of such associations and of such a predisposition if it exists. There have been a number of publications detailing clinical presentations suggestive of inflammatory neuropathy in patients with a known or later proven genetic aetiology, and subsequently felt to be part of the phenotype rather than representing an association. A number of genetically mediated multisystemic diseases with neuropathy have otherwise been reported as mimicking chronic inflammatory demyelinating polyneuropathy (CIDP). The most common example is that of familial amyloid polyneuropathy, of particular concern for the clinician when misdiagnosed as CIDP, in view of the therapeutic implications. We review the literature on reported associations, mimics and misdiagnoses of hereditary and inflammatory neuropathy and attempt to determine a practical approach to the problem in clinical practice using clinical features, electrophysiology, histopathology and targeted early genetic testing. The issue of attempting immunomodulatory therapy is discussed in view of the published literature. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
38. Mutations in XRCC1 cause cerebellar ataxia and peripheral neuropathy.
- Author
-
O'Connor, Emer, Vandrovcova, Jana, Bugiardini, Enrico, Chelban, Viorica, Manole, Andreea, Davagnanam, Indran, Wiethoff, Sarah, Pittman, Alan, Lynch, David S., Efthymiou, Stephanie, Marino, Silvia, Manzur, Adnan Y., Roberts, Mark, Hanna, Michael G., Houlden, Henry, Matthews, Emma, and Wood, Nicholas W.
- Subjects
GENETIC mutation ,CEREBELLAR ataxia ,NEUROPATHY ,GENETIC disorders ,PHENOTYPES - Published
- 2018
- Full Text
- View/download PDF
39. Bilateral facial weakness with paraesthesia variant of Guillain-Barré syndrome following Vaxzevria COVID-19 vaccine.
- Author
-
Bonifacio, Guendalina Beatrice, Patel, Dharmini, Cook, Sarah, Purcaru, Elena, Couzins, Michael, Domjan, Janine, Ryan, Suzanne, Alareed, Ahmad, Tuohy, Orla, Slaght, Sean, Furby, Julian, Allen, David, Katifi, Haider A., and Kinton, Lucy
- Subjects
GUILLAIN-Barre syndrome ,LEG pain ,COVID-19 vaccines ,FACIAL pain ,HUMAN herpesvirus 1 - Published
- 2022
- Full Text
- View/download PDF
40. Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy.
- Author
-
Hiu Yi Wong, Anna, Fukami, Yuki, Sudo, Makoto, Kokubun, Norito, Hamada, Shinsuke, Yuki, Nobuhiro, and Wong, Anna Hiu Yi
- Subjects
- *
INTRAVENOUS immunoglobulins , *THERAPEUTIC use of immunoglobulins , *DEMYELINATION , *NEUROPATHY , *NERVOUS system abnormalities , *PHYSIOLOGY , *THERAPEUTICS , *GLYCOSYLATION , *IMMUNOGLOBULINS , *GUILLAIN-Barre syndrome , *CASE-control method - Abstract
Objective: Sialylation in Fc portion of IgG plays a crucial role in the pathogenesis of autoimmune diseases and the working mechanism of intravenous immunoglobulin (IVIG). We aim to test whether IgG-Fc sialylation is a biomarker of disease activity for chronic inflammatory demyelinating polyneuropathy (CIDP).Methods: By using specific lectins for sialylation, galactosylation and agalactosylation, lectin-enzyme assay and lectin blotting with pretreatment of IgG degradating enzyme of Streptococcus pyogenes were performed to compare the glycosylation levels of serum IgG-Fc (1) between patients of untreated CIDP (n=107) and normal control subjects (n=27), (2) among patients with untreated CIDP of different clinical severities and (3) before and after IVIG treatment of patients with CIDP (n=12).Results: Sialylation and galactosylation of IgG-Fc were significantly reduced in patients with CIDP than normal control subjects (p=0.003 and 0.033, respectively), whereas agalactosylation was increased in CIDP (p=0.21). Ratios of sialylated/agalactosylated IgG-Fc levels were significantly reduced in CIDP (p<0.001) and inversely related to disease severity (p=0.044). After IVIG treatment, levels of sialylated IgG-Fc significantly increased (p=0.003).Conclusions: Sialylation of IgG-Fc is reduced in CIDP. Its level correlated with clinical severity and increased after IVIG treatment. Sialylated as well as ratio of sialylated/agalactosylated IgG-Fc could be new measures to monitor the disease severity and treatment status in CIDP. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
41. Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy.
- Author
-
Antoine, Jean-Christophe, Boutahar, Nadia, Lassablière, François, Reynaud, Evelyne, Ferraud, Karine, Rogemond, Véronique, Paul, Stéphane, Honnorat, Jérôme, and Camdessanché, Jean-Philippe
- Subjects
- *
FIBROBLAST growth factor receptors , *NEUROPATHY , *AUTOIMMUNE diseases , *IMMUNOGLOBULINS , *NEUROLOGICAL disorders , *HUMAN proteins , *ENZYME-linked immunosorbent assay , *IMMUNOGLOBULIN analysis , *ANTIGEN-antibody reactions , *CELL receptors , *EPITHELIAL cells , *IMMUNITY , *NERVE tissue proteins , *PERIPHERAL neuropathy , *SENSORY receptors , *PREDICTIVE tests , *RETROSPECTIVE studies ,PERIPHERAL neuropathy diagnosis - Abstract
Background: Immunological mechanisms are suspected in sensory neuropathy (SN) occurring with systemic autoimmune diseases and in some idiopathic cases, but so far there are no antibodies (Abs) identifying these neuropathies.Methods: In the search for such specific antibodies, serum samples were collected from 106 patients with SN of these 72 fulfilled the diagnosis criteria of sensory neuronopathy (SNN) and 211 control subjects including patients with sensorimotor neuropathies, other neurological diseases (ONDs), systemic autoimmune diseases and healthy blood donors.Results: In the first step, a protein array with 8000 human proteins allowed identification of the intracellular domain of the fibroblast growth factor receptor 3 (FGFR3) as a target of Abs in 7/16 SNN and 0/30 controls. In the second step, an ELISA method was used to test the 317 patients and controls for anti-FGFR3 Abs. Abs were detected in 16/106 patients with SN and 1/211 controls (p<0.001). Among the 106 patients with SN, anti-FGFR3 Abs were found in 11/38 patients with autoimmune context, 5/46 with idiopathic neuropathy and 0/22 with neuropathy of other aetiology (p=0.006). The only control patient with anti-FGFR3 Abs had lupus and no recorded neuropathy. Sensitivity, specificity, and positive and negative predictive values of anti-FGFR3 Abs for a diagnosis of idiopathic or dysimmune SN were 19%, 99.6%, 94.1% and 77.3%, respectively. A cell-based assay confirmed serum reactivity against the intracellular domain of FGFR3. The neuropathy in patients with anti-FGF3 Abs was non-length dependent in 87% of patients and fulfilled the criteria of probable SNN in 82%. Trigeminal nerve involvement and pain were frequent features.Conclusions: A anti-FGFR3 Abs identify a subgroup of patients with SN in whom an underlying autoimmune disorder affecting sensory neurons in the dorsal root and trigeminal nerve ganglia is suspected. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
42. Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy.
- Author
-
Satoshi Kuwabara, Sagiri Isose, Masahiro Mori, Satsuki Mitsuma, Setsu Sawai, Minako Beppu, Yukari Sekiguchi, Sonoko Misawa, Kuwabara, Satoshi, Isose, Sagiri, Mori, Masahiro, Mitsuma, Satsuki, Sawai, Setsu, Beppu, Minako, Sekiguchi, Yukari, and Misawa, Sonoko
- Subjects
- *
ELECTROPHYSIOLOGY , *NEUROPATHY , *INFLAMMATION , *DATA analysis , *DEMYELINATION , *KAPLAN-Meier estimator , *PLASMAPHERESIS , *IMMUNOGLOBULINS , *THERAPEUTIC use of immunoglobulins , *TREATMENT of Guillain-Barre syndrome , *ADRENOCORTICAL hormones , *COMPARATIVE studies , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *NEURAL conduction , *GUILLAIN-Barre syndrome , *PROGNOSIS , *RESEARCH , *TIBIAL nerve , *EVALUATION research , *TREATMENT effectiveness , *THERAPEUTICS - Abstract
Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is currently classified into 'typical' CIDP and 'atypical' subtypes such as multifocal acquired demyelinating sensory and motor neuropathy (MADSAM).Objectives: To assess the frequency of CIDP subtypes, and to elucidate clinical and electrophysiological features, and treatment response in each subtype.Methods: We reviewed data from 100 consecutive patients fulfilling criteria for CIDP proposed by the European Federation of Neurological Societies and the Peripheral Nerve Society. The Kaplan-Meier curve was used to estimate long-term outcome.Results: Patients were classified as having typical CIDP (60%), MADSAM (34%), demyelinating acquired distal symmetric neuropathy (8%) or pure sensory CIDP (1%). Compared with patients with MADSAM, patients with typical CIDP showed more rapid progression and severe disability, and demyelination predominant in the distal nerve segments. MADSAM was characterised by multifocal demyelination in the nerve trunks. Abnormal median-normal sural sensory responses were more frequently found for typical CIDP (53% vs 13%). Patients with typical CIDP invariably responded to corticosteroids, immunoglobulin or plasmapheresis, whereas patients with MADSAM were more refractory to these treatments. The Kaplan-Meier analyses showed that 64% of patients with typical CIDP and 41% of patients with MADSAM had a clinical remission 5 years later (p=0.02).Conclusions: Among the CIDP spectrum, typical CIDP and MADSAM are the major subtypes, and their pathophysiology appears to be distinct. In typical CIDP, the distal nerve terminals and possibly the nerve roots, where the blood-nerve barrier is anatomically deficient, are preferentially affected, raising the possibility of antibody-mediated demyelination, whereas cellular immunity with breakdown of the barrier may be important in MADSAM neuropathy. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
43. Peripheral neuropathy in ALS: phenotype association.
- Author
-
deCarvalho, Mamede, Gromicho, Marta, Andersen, Peter, Grosskreutz, Julian, Kuzma-Kozakiewicz, Magdalena, Petri, Susanne, Uysal, Hilmi, and Pinto, Susana
- Subjects
PERIPHERAL neuropathy ,PHENOTYPES ,PERIPHERAL nerve injuries ,MOTOR neuron diseases ,AMYOTROPHIC lateral sclerosis ,RESEARCH ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,LONGITUDINAL method ,DISEASE complications - Published
- 2021
- Full Text
- View/download PDF
44. Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies
- Author
-
Giulia Berzero, Nathalie Gaspar, Thierry Maisonobe, Capucine Mouthon-Reignier, Julien Lazarovici, Timothée Lenglet, A. K. Wang, Corinne Dupel-Pottier, Weiss Nicolas, Karine Viala, Patrice Carde, David H. Adams, Kevin Bihan, Cécile Cauquil, Guillaume Fargeot, Benramdane Riad, Andoni Echaniz-Laguna, Dimitri Psimaras, Camille Tafani, Laurent Magy, Laure Thomas, Maeva Stephant, Fargeot, G., Dupel-Pottier, C., Stephant, M., Lazarovici, J., Thomas, L., Mouthon-Reignier, C., Riad, B., Carde, P., Berzero, G., Tafani, C., Nicolas, W., Viala, K., Maisonobe, T., Lenglet, T., Wang, A., Magy, L., Bihan, K., Gaspar, N., Adams, D., Echaniz-Laguna, A., Cauquil, C., and Psimaras, D.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Neurology ,Antineoplastic Agents ,Guillain-Barre Syndrome ,Gastroenterology ,Young Adult ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Brentuximab vedotin ,Adverse effect ,Aged ,Brentuximab Vedotin ,Hematology ,business.industry ,Lymphoma, Non-Hodgkin ,Polyradiculoneuropathy ,Middle Aged ,medicine.disease ,Hodgkin Disease ,Lymphoma ,Psychiatry and Mental health ,Peripheral neuropathy ,Polyradiculoneuropathy, Chronic Inflammatory Demyelinating ,Monomethyl auristatin E ,chemistry ,oncology ,haematology ,neuropathy ,Female ,Surgery ,neuromuscular ,Neurology (clinical) ,neurophysiology ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Brentuximab vedotin (BV) is an antibody-drug conjugate composed by an anti-CD30 monoclonal antibody and the anti-microtubule agent monomethyl auristatin E, used for the treatment of relapsed/refractory Hodgkin's lymphoma and non-Hodgkin's lymphoma. Peripheral neuropathy is a frequent adverse event of BV treatment, affecting up to 60% to 70% of patients.1 It usually consists of a mild axonal, length-dependent, sensory neuropathy, characterised by numbness and tingling of fingers and toes,1 2 related to the toxic effect of monomethyl auristatin E on axonal microtubules.3 Nonetheless, immune-mediated peripheral neuropathies characterised by prominent motor impairment have also been described,4 suggesting that, similarly to other antineoplastic agents, BV might have the potential to induce or exacerbate inflammatory polyradiculoneuropathies. The aim of this study was to assess the characteristics of inflammatory demyelinating polyradiculoneuropathy associated with BV treatment. ### Patients and methods We performed a retrospective research in seven French neurology departments, for all patients who were admitted between January 2013 and December 2019 to investigate a peripheral neuropathy appeared during BV treatment. We selected patients meeting Sjevar et al criteria for the diagnosis of Guillain-Barre syndrome (GBS) (level 1 of diagnostic certainty) or meeting ‘definite’ criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) according to 2010 European Federation of Neurological Societies/Peripheral Nerve Society guideline. We considered the onset as acute, subacute or chronic if the disease nadir was reached within 4 weeks, between 4 to 8 …
- Published
- 2020
45. VEXAS syndrome extends the neurological complications of haemopathies.
- Author
-
Corcia, Philippe
- Subjects
NEUROLOGICAL disorders ,GENETIC mutation ,DISEASE complications - Published
- 2022
- Full Text
- View/download PDF
46. Prion-related peripheral neuropathy in sporadic Creutzfeldt-Jakob disease
- Author
-
Sabina Capellari, Piero Parchi, Maurizio Moggio, Patrizia Sola, Alessia Franceschini, Armin Giese, Veronica Redaelli, Anna Magherini, Paola Caroppo, Marcello Rossi, Anna Ladogana, Paolo Ripellino, Paolo Fociani, Simone Baiardi, Byron Caughey, Baiardi S., Redaelli V., Ripellino P., Rossi M., Franceschini A., Moggio M., Sola P., Ladogana A., Fociani P., Magherini A., Capellari S., Giese A., Caughey B., Caroppo P., and Parchi P.
- Subjects
Myoclonus ,Amyloid ,Pathology ,medicine.medical_specialty ,Disease ,Electromyography ,Rapidly progressive dementia ,Creutzfeldt-Jakob Syndrome ,Prion Proteins ,03 medical and health sciences ,0302 clinical medicine ,Sural Nerve ,medicine ,Humans ,Peripheral Nerves ,Tropism ,Nerve biopsy ,medicine.diagnostic_test ,business.industry ,Peripheral Nervous System Diseases ,Creutzfeldt-jakob disease ,medicine.disease ,Sciatic Nerve ,Neuropathy ,Encephalopathy, Bovine Spongiform ,Peripheral neuropathology ,Psychiatry and Mental health ,medicine.anatomical_structure ,Peripheral neuropathy ,Peripheral nervous system ,Prion ,Ataxia ,Surgery ,Neurology (clinical) ,Sciatic nerve ,business ,030217 neurology & neurosurgery ,Demyelinating Diseases - Abstract
ObjectiveTo assess whether the involvement of the peripheral nervous system (PNS) belongs to the phenotypic spectrum of sporadic Creutzfeldt-Jakob disease (sCJD).MethodsWe examined medical records of 117 sCJDVV2 (ataxic type), 65 sCJDMV2K (kuru-plaque type) and 121 sCJDMM(V)1 (myoclonic type) subjects for clinical symptoms, objective signs and neurophysiological data. We reviewed two diagnostic nerve biopsies and looked for abnormal prion protein (PrPSc) by western blotting and real-time quaking-induced conversion (RT-QuIC) in postmortem PNS samples from 14 subjects.ResultsSeventy-five (41.2%) VV2-MV2K patients, but only 11 (9.1%) MM(V)1, had symptoms or signs suggestive of PNS involvement occurring at onset in 18 cases (17 VV2-MV2K, 9.3%; and 1 MM(V)1, 0.8%) and isolated in 6. Nerve biopsy showed a mixed predominantly axonal and demyelinating neuropathy in two sCJDMV2K. Electromyography showed signs of neuropathy in half of the examined VV2-MV2K patients. Prion RT-QuIC was positive in all CJD PNS samples, whereas western blotting detected PrPSc in the sciatic nerve in one VV2 and one MV2K.ConclusionsPeripheral neuropathy, likely related to PrPSc deposition, belongs to the phenotypic spectrum of sCJDMV2K and VV2 and may mark the clinical onset. The significantly lower prevalence of PNS involvement in typical sCJDMM(V)1 suggests that the PNS tropism of sCJD prions is strain dependent.
- Published
- 2018
47. SANDO syndrome in a cohort of 107 patients with CPEO and mitochondrial DNA deletions.
- Author
-
Hanisch, Frank, Kornhuber, Malte, Alston, Charlotte L., Taylor, Robert W., Deschauer, Marcus, and Zierz, Stephan
- Subjects
- *
EYE paralysis , *NEUROPATHY , *DYSARTHRIA , *MITOCHONDRIAL DNA abnormalities , *DELETION mutation - Abstract
Objective: The sensory ataxic neuropathy with dysarthria and ophthalmoparesis (SANDO) syndrome is a subgroup of mitochondrial chronic progressive external ophthalmoplegia (CPEO)-plus disorders associated with multiple mitochondrial DNA (mtDNA) deletions. There is no systematic survey on SANDO in patients with CPEO with either single or multiple large-scale mtDNA deletions. Methods: In this retrospective analysis, we characterised the frequency, the genetic and clinical phenotype of 107 index patients with mitochondrial CPEO (n=66 patients with single and n=41 patients with multiple mtDNA deletions) and assessed these for clinical evidence of a SANDO phenotype. Patients with multiple mtDNA deletions were additionally screened for mutations in the nuclear-encoded POLG, SLC25A4, PEO1 and RRM2B genes. The clinical, histological and genetic data of 11 patients with SANDO were further analysed. Results: None of the 66 patients with single, largescale mtDNA deletions fulfilled the clinical criteria of SANDO syndrome. In contrast, 9 of 41 patients (22%) with multiple mtDNA deletions and two additional family members fulfilled the clinical criteria for SANDO. Within this subgroup, multiple mtDNA deletions were associated with the following nuclear mutations: POLG (n=6), PEO1 (n=2), unidentified (n=2). The combination of sensory ataxic neuropathy with ophthalmoparesis (SANO) was observed in 70% of patients with multiple mtDNA deletions but only in 4% with single deletions. The combination of CPEO and sensory ataxic neuropathy (SANO, incomplete SANDO) was found in 43% of patients with multiple mtDNA deletions but not in patients with single deletions. Conclusion: The SANDO syndrome seems to indicate a cluster of symptoms within the wide range of multisystemic symptoms associated with mitochondrial CPEO. SANO seems to be the most frequent phenotype associated with multiple mtDNA deletions in our cohort but not or is rarely associated with single, large-scale mtDNA deletions. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
48. Electrodiagnosis of GBS subtypes by a single study: not yet the squaring of the circle.
- Author
-
Uncini, Antonino, Zappasodi, Filippo, and Notturno, Francesca
- Subjects
- *
GUILLAIN-Barre syndrome , *NEUROPATHY , *ELECTRODIAGNOSIS , *NEURAL stimulation , *ELECTROPHYSIOLOGY - Abstract
The article offers information on a study on Guillain-Barré syndrome (GBS) and electrodiagnosis of GBS subtypes. Topics discussed include important role of electrophysiology GBS diagnosis, electrodiagnosis of acute inflammatory demyelinating neuropathy (AIDP) and acute motor axonal neuropathy (AMAN), limitations of the study such as temporal dispersion and increased duration of compound muscle action potentials (CMAP) and difficulty faced in everyday practice of GBS electrodiagnosis.
- Published
- 2015
- Full Text
- View/download PDF
49. Is overwork weakness relevant in Charcot-Marie-Tooth disease?
- Author
-
Piscosquito, G., Reilly, M. M., Schenone, A., Fabriz, G. M., Cavallaro, T., Santoro, L., Vita, G., Quattrone, A., Padua, L., Gemignani, F., Visiol, F., Laurà, M., Calabrese, D., Hughes, R. A. C., Radice, D., Solari, A., and Pareyson, D.
- Subjects
- *
MENTAL fatigue , *ASTHENIA , *CHARCOT-Marie-Tooth disease , *NEUROMUSCULAR diseases , *NEUROPATHY - Abstract
Background In overwork weakness (OW), muscles are increasingly weakened by exercise, work or daily activities. Although it is a well-established phenomenon in several neuromuscular disorders, it is debated whether it occurs in Charcot-Marie-Tooth disease (CMT). Dominant limb muscles undergo a heavier overload than non-dominant and therefore if OW occurs we would expect them to become weaker. Four previous studies, comparing dominant and non-dominant hand strength in CMT series employing manual testing or myometry, gave contradictory results. Moreover, none of them examined the behaviour of lower limb muscles. Methods We tested the OW hypothesis in 271 CMT1A adult patients by comparing bilateral intrinsic hand and leg muscle strength with manual testing as well as manual dexterity. Results We found no significant difference between sides for the strength of first dorsal interosseous, abductor pollicis brevis, anterior tibialis and triceps surae. Dominant side muscles did not become weaker than non-dominant with increasing age and disease severity (assessed with the CMT Neuropathy Score); in fact, the dominant triceps surae was slightly stronger than the non-dominant with increasing age and disease severity. Discussion Our data does not support the OW hypothesis and the consequent harmful effect of exercise in patients with CMT1A. Physical activity should be encouraged, and rehabilitation remains the most effective treatment for CMT patients. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
50. Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy.
- Author
-
Vlam, Lotte, Cats, Elisabeth A., Willemse, Eline, Franssen, Hessel, Medic, Jelena, Piepers, Sanne, Veldink, Jan H., van den Berg, Leonard H., and van der Po, W-Ludo
- Subjects
- *
PHARMACOKINETICS , *THERAPEUTIC use of immunoglobulins , *NEUROPATHY , *INTRAVENOUS therapy , *BIOMARKERS , *GENETIC polymorphisms , *THERAPEUTICS - Abstract
Background Multifocal motor neuropathy (MMN) is often responsive to treatment with intravenous immunoglobulin (IVIg), but the optimal dose and intervals of IVIg maintenance treatment have not been established. Increase in IgG concentration (ΔIgG) after IVIg infusion has recently been identified as determinant of outcome in Guillain-Barré syndrome. ΔIgG may therefore represent a potentially useful biomarker to optimise IVIg dosing in patients with MMN. Objective The aims of this study were to determine variability of IVIg pharmacokinetics in patients with MMN in relation to treatment response, and to establish whether interindividual differences in IVIg pharmacokinetics were associated with genetic polymorphisms of the endothelial IgG receptor (FcRn) which determines IgG half-life Methods Twenty-three patients with MMN receiving their first IVIg treatment at a cumulative dose of 2.0 g/ kg in 5 days were included. A good treatment response was defined as an increase in muscle strength of at least one Medical Research Council point in minimally two muscle groups. IgG concentrations in serum were determined at baseline, at day 1 and day 5 of the IVIg course, and 3 weeks after treatment. FcRn copy number variation and differences in repeat length of the variable number of tandem repeats in the FcRn gene were determined by quantitative PCR and Sanger sequencing. response to treatment. Total IgG and AIgG levels showed large variation between patients. Mean ΔIgG was higher in IVIg responders than in non-responders, with the largest difference on day 1 (11.1 g/L vs 4.5 g/L, p=0.06), but our study lacked power to show statistically significant differences. Genetic variation in the FcRn gene was not associated with ΔIgG levels or response to treatment Conclusions IVIg pharmacokinetics varies in patients with MMN and may be associated with clinical response [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.